Daily Cosmetic Research Analysis
Three high-impact cosmetic studies stand out: a multicenter phase III RCT shows an animal-component–free botulinum toxin (CKDB-501A) is non-inferior to onabotulinumtoxinA for glabellar lines; a double-blind RCT demonstrates a cyclized hexapeptide-9 outperforms retinol on multiple wrinkle metrics; and a randomized clinical trial in blepharoplasty optimizes local anesthesia to markedly reduce perioperative pain and early bruising. Collectively, these works advance safer injectables, next-generatio
Summary
Three high-impact cosmetic studies stand out: a multicenter phase III RCT shows an animal-component–free botulinum toxin (CKDB-501A) is non-inferior to onabotulinumtoxinA for glabellar lines; a double-blind RCT demonstrates a cyclized hexapeptide-9 outperforms retinol on multiple wrinkle metrics; and a randomized clinical trial in blepharoplasty optimizes local anesthesia to markedly reduce perioperative pain and early bruising. Collectively, these works advance safer injectables, next-generation topical anti-aging, and patient-centered perioperative protocols.
Research Themes
- Animal-component–free neuromodulators for aesthetic indications
- Peptide-based anti-aging surpassing retinoids
- Perioperative anesthesia optimization to improve patient experience
Selected Articles
1. Efficacy and Safety of CKDB-501A in Treating Moderate-To-Severe Glabellar Lines: A Randomized, Double-Blind, Active-Controlled, Multi-Center Phase III Trial.
In a multicenter, double-blind phase III trial (n=300), an animal-component–free botulinum toxin (CKDB-501A) demonstrated non-inferiority to onabotulinumtoxinA for glabellar lines with 80.69% vs 70.83% achieving ≥2-point FWS improvement at week 4. Efficacy was sustained to 16 weeks, and no neutralizing antibodies or hypersensitivity events were observed.
Impact: This head-to-head phase III RCT supports a fully animal-component–free neuromodulator as a safe, effective alternative, addressing biocompatibility and immunogenicity concerns relevant to broad aesthetic practice.
Clinical Implications: CKDB-501A can be considered an effective alternative to onabotulinumtoxinA for moderate-to-severe glabellar lines, with the potential advantage of avoiding human serum albumin and minimizing hypersensitivity/antibody concerns. Clinicians may expect comparable 4–16 week efficacy profiles.
Key Findings
- Week-4 ≥2-point FWS improvement: CKDB-501A 80.69% vs onabotulinumtoxinA 70.83% (non-inferior; 95% CI 0.09–19.55; p=0.0491).
- Sustained efficacy through 16 weeks with ~70% maintaining ≥1-point improvement.
- Comparable safety; no events from local/distant spread, no hypersensitivity, and no neutralizing antibodies detected.
- Secondary photo-assessed and subject-reported outcomes aligned with primary efficacy.
Methodological Strengths
- Randomized, double-blind, active-controlled multicenter phase III design
- Clinically meaningful, predefined endpoints with sustained follow-up to 16 weeks
Limitations
- Single treatment cycle with follow-up limited to 16 weeks
- Non-inferiority framework; superiority and long-term immunogenicity not established
Future Directions: Evaluate durability across repeated cycles, dose–response equivalence, real-world safety, and subgroup responses (e.g., prior toxin exposure, diverse skin types).
BACKGROUND: Botulinum toxin is a key treatment for dynamic wrinkles. OBJECTIVE: This study evaluates CKDB-501A, a botulinum toxin completely free from animal-derived components including human-serum albumin, comparing its efficacy and safety to onabotulinumtoxinA (ONA) for the treatment of moderate-to-severe glabellar lines. METHODS: In this phase 3 trial, 300 subjects with moderate-to-severe glabellar lines were randomized to receive CKDB-501A or ONA. The primary efficacy endpoint was the investigator-assessed improvement rate for frowning at week 4, defined as a ≥ 2-point improvement from baseline on the 4-point Facial Wrinkle Scale (FWS). Secondary efficacy endpoints included photo-assessed improvement rates and subjects' overall assessment and satisfaction. Safety was evaluated by the monitoring of adverse events (AEs) and neutralizing antibodies formation. RESULTS: At week 4, 80.69% of the CKDB-501A group achieved a ≥ 2-point improvement in FWS score versus 70.83% for ONA, confirming non-inferiority (95% CI: 0.09-19.55, p = 0.0491). Secondary endpoints showed no significant differences between groups, with sustained efficacy up to 16 weeks. Approximately 70% maintained at least a 1-point improvement. Photo-assessed and subjects' overall improvement and satisfaction rates were consistent with primary findings. Both treatments had comparable safety profiles, with no AEs related to the local and distant spread of toxin, hypersensitivity reactions, or neutralizing antibodies formation. CONCLUSION: CKDB-501A is a safe and effective alternative to existing botulinum toxin products for treating moderate-to-severe glabellar lines, offering benefits of improved biocompatibility and reduced risk of allergic reactions. CLINICALTRIALS: gov: NCT05804656.
2. Novel Cyclized Hexapeptide-9 Outperforms Retinol Against Skin Aging: A Randomized, Double-Blinded, Active- and Vehicle-Controlled Clinical Trial.
In a double-blind, active- and vehicle-controlled trial over 56 days, cyclized hexapeptide-9 significantly improved the number, area, and roughness of crow’s feet and forehead wrinkles, outperforming retinol on most outcomes. Effects appeared to augment over time, supporting peptide cyclization as a viable anti-aging strategy.
Impact: This trial provides head-to-head evidence that a next-generation peptide can surpass retinol on key clinical wrinkle metrics, potentially reshaping first-line topical anti-aging approaches.
Clinical Implications: CHP-9 may serve as an effective alternative for patients intolerant to retinoids or seeking improved efficacy with potentially favorable tolerability; integration into long-term regimens merits consideration.
Key Findings
- CHP-9 significantly reduced number, area, and roughness of crow’s feet and forehead wrinkles; retinol improved fewer parameters.
- Magnitude of effect favored CHP-9 over retinol on most outcomes except crow’s feet roughness.
- Time-dependent augmentation observed with continued CHP-9 use over 56 days.
Methodological Strengths
- Randomized, double-blind, active- and vehicle-controlled design
- Objective wrinkle assessments with reported confidence intervals
Limitations
- Sample size not reported in abstract and short 56-day duration
- Safety/tolerability outcomes not detailed in the abstract
Future Directions: Confirm long-term safety and durability, define mechanisms and optimal concentrations, and assess performance across diverse skin types and phototypes.
BACKGROUND: The functionality and regenerative capacity of skin progressively deteriorate with aging. Topical use of peptides with a hyper-safety profile has been implicated in replacing retinol for skin anti-aging use, but is limited due to low stability and poor skin permeability. AIMS: In this randomized, double-blinded, active- and vehicle-controlled clinical trial, we aim to evaluate the efficacy of an innovative cyclized hexapeptide-9 (CHP-9) with increased stability and skin permeability on skin aging compared to retinol. METHODS: Healthy volunteers with aging skin were randomly assigned to twice-daily topical use of 0.002% CHP-9 serum, 0.002% retinol serum, or vehicle serum for 56 days. RESULTS: CHP-9 treatment significantly decreased the number, area, and roughness of both crow's feet (-2.20, 95% CI: -4.38, -0.03; -3.95, 95% CI: -5.80, -2.11; -1.95, 95% CI: -3.30, -0.59, respectively) and forehead wrinkles (-2.88, 95% CI: -4.21, -1.56; -4.90, 95% CI: -5.97, -3.82; -3.96, 95% CI: -5.92, -2.01, respectively), while retinol only decreased the area of crow's feet (-2.23, 95% CI: -3.86, -0.60) and the number and area of forehead wrinkles (-1.05, 95% CI:-1.69, -0.41). Except for the roughness of crow's feet, CHP-9 demonstrated significantly larger extent of effects than retinol did on all other outcomes. Furthermore, long-term use of CHP-9 showed time-dependent augmentation in its potency to reduce the number of crow's feet, and the number, area, and roughness of forehead wrinkles. CONCLUSIONS: In conclusion, CHP-9 is more potent than retinol in improving skin aging-related symptoms, especially for long-term use. Cyclization of collagen peptides may present a preventive/therapeutic option for skin aging.
3. More Comfortable Enjoyment for Upper Eyelid Blepharoplasty: Optimization of Anesthesia Methods Using Stepwise Local Anesthesia Technique.
In a randomized clinical trial of 184 blepharoplasty patients, a stepwise local anesthesia protocol (ropivacaine+lidocaine with graded epinephrine) significantly lowered intraoperative pain across all timepoints, reduced reflex tearing, and improved 7-day ecchymosis/erythema/swelling, yielding higher patient satisfaction. Differences were not evident at 1 month.
Impact: A pragmatic, easily adoptable anesthesia optimization improves patient experience and early recovery without additional devices or costs, directly informing daily cosmetic surgical practice.
Clinical Implications: Adopting a stepwise local anesthesia protocol can reduce intraoperative discomfort and early bruising/erythema/swelling in upper blepharoplasty, likely enhancing satisfaction and clinic workflow through smoother recoveries.
Key Findings
- Stepwise anesthesia significantly reduced VAS pain at all measured timepoints (T0–T5, all p<0.001).
- Lower incidence of reflexive lacrimation vs conventional anesthesia (p<0.01).
- Improved periorbital appearance at day 7 (less ecchymosis, erythema, swelling; all p<0.05).
- Higher patient satisfaction (p=0.016); no between-group differences at 1 month.
Methodological Strengths
- Prospective randomized design with adequate sample size (n=184)
- Multiple clinically relevant outcomes (pain, tearing, bruising/erythema/swelling, satisfaction)
Limitations
- Single-center setting and short-term outcomes; blinding not described
- No assessment of long-term edema/fibrosis or cost-effectiveness
Future Directions: Validate in multicenter settings, explore standardized dosing algorithms, and evaluate applicability to other oculoplastic/cosmetic procedures.
BACKGROUND: Perceived pain during local anesthesia injections in double-eyelid blepharoplasty can be influenced by both the epinephrine concentration and local anesthetics components. This study aimed to explore a new stepwise local anesthesia method for upper eyelid blepharoplasty, utilizing ropivacaine mixed with lidocaine, stepwise increase in epinephrine concentration infiltration, and stepwise specific anesthesia application during two surgical procedures. METHODS: A prospective randomized clinical trial was conducted on a cohort of patients undergoing upper double-eyelid blepharoplasty, who were randomly divided into two distinct groups: conventional local anesthesia and stepwise anesthetic method. The operative perception pain (VAS), reflexive lacrimation, postoperative periorbital appearance, and patient satisfaction were compared between the two groups. RESULTS: A total of 184 patients were included and randomized. The mean visual analog scale (VAS) of the stepwise local anesthesia group was significantly lower than control (T0-T5, all P < 0.001). Meanwhile as for the probability of reflexive lacrimation, stepwise local anesthesia group was lower than control method (P < 0.01). With regard to the periorbital appearance, there are significant differences between two groups in Day 7 at ecchymosis, erythema, and swelling (P < 0.05), and the stepwise local anesthesia method group was lower than control group. However, in 1 month there are no significant differences between two groups. The satisfaction of stepwise local anesthesia group was higher than control (P = 0.016). CONCLUSION: In summary, the stepwise local anesthesia technique employed in upper eyelid blepharoplasty demonstrates superior efficacy compared to conventional anesthesia. This technique effectively mitigates pain and immediate postoperative appearance, thereby resulting in heightened patient contentment and justifying its continued endorsement. LEVEL OF EVIDENCE I: This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266 .